Dossier
Hemab
Coverage of Hemab in the Nexus archive.
- Novo-Backed Biotech Hemab Raises $301.5 Million in Upsized IPO
Hemab, a biotech company backed by Novo, raised $301.5 million in an upsized IPO. The funding will support its focus on blood-related clinical research and development.
- Novo-Backed Biotech Hemab Seeks to Raise $212 Million in US IPO
Hemab, a biotech company backed by Novo, is seeking to raise $212 million through a US IPO. The company is focused on medical research and development.